Introduction Despite representing only 3% of the US population, immunocompromised (IC)
individuals account for nearly half of the COVID-19 breakthrough hospitalizations. IC …

The clinical evolution of patients infected with the Severe Acute Respiratory Coronavirus
type 2 (SARS-CoV-2) depends on the complex interplay between viral and host factors. The …

Background Solid organ transplant recipients (SOTRs) are at high‐risk for severe infection
from severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). Anti‐spike …

Tixagevimab-cilgavimab is authorized for preexposure prophylaxis against coronavirus
disease 2019 (COVID-19) in immunocompromised hosts. Herein, we report the clinical …

Rationale & Objective Neutralizing monoclonal antibody treatments have shown promising
preliminary results in kidney transplant recipients infected with severe acute respiratory …

As solid organ transplant recipients are at high risk of severe COVID-19 and respond poorly
to primary SARS-CoV-2 mRNA vaccination, they have been prioritized for booster …

Background Sotrovimab is a neutralizing monoclonal antibody (mAb) that seems to remain
active against recent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …

The aim of the study was to explore the humoral and T-cell response in lung transplant (LuT)
patients. Two-time points were considered, before (T0) and after (Tpost) the third dose of the …

Background With the rapid evolution of the severe acute respiratory syndrome coronavirus 2
(SARS‐CoV‐2) pandemic, the development of effective and safe vaccines was of utmost …

Neutralizing antispike monoclonal antibody (mAb) therapies were highly efficacious in
preventing coronavirus disease 2019 (COVID‐19) hospitalization. While severe acute …